Moreover, formulation-compatibility studies of novel skin cancer prevention/treatment molecules such as the toll-like receptor 4 (TLR4) antagonist resatorvid (TAK-242) [226] demonstrated that among different types of formulation, one of the best for drug retention and permeation effectiveness was a gel-based formulation [227]. The gene discussed is TLR4; the disease is skin neoplasm.